Veterinary Medicines

Bovalto Respi 3, Suspension for injection

Authorised
  • Bovine respiratory syncytial virus, strain BIO-24, Inactivated
  • Bovine parainfluenza virus 3, strain BIO-23, Inactivated
  • Mannheimia haemolytica, serotype A1, strain DSM 5283, Inactivated
Download as PDF

Product identification

Medicine name:
Bovalto Respi 3, Suspension for injection
Bovalto Respi 3 Suspensie voor injectie
Bovalto Respi 3 Suspension injectable
Bovalto Respi 3 Injektionssuspension
Active substance:
  • Bovine respiratory syncytial virus, strain BIO-24, Inactivated
  • Bovine parainfluenza virus 3, strain BIO-23, Inactivated
  • Mannheimia haemolytica, serotype A1, strain DSM 5283, Inactivated
Target species:
  • Cattle
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Bovine respiratory syncytial virus, strain BIO-24, Inactivated
    1.00
    relative potency
    /
    1.00
    Dose
  • Bovine parainfluenza virus 3, strain BIO-23, Inactivated
    1.00
    relative potency
    /
    1.00
    Dose
  • Mannheimia haemolytica, serotype A1, strain DSM 5283, Inactivated
    1.00
    relative potency
    /
    1.00
    Dose
Pharmaceutical form:
  • Suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Cattle
      • Milk
        0
        hour
      • Meat and offal
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI02AL
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Belgium
Available in:
  • Belgium
Package description:
  • Plastic Vial 10 x 5.0 Dose
  • Glass Vial 10 x 5.0 Dose
  • Plastic Vial 1 x 50.0 Dose
  • Glass Vial 1 x 50.0 Dose
  • Plastic Vial 1 x 25.0 Dose
  • Glass Vial 1 x 25.0 Dose
  • Plastic Vial 1 x 5.0 Dose
  • Glass Vial 1 x 5.0 Dose
  • Plastic Vial 10 x 5.0 Dose
  • Glass Vial 10 x 5.0 Dose

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Boehringer Ingelheim Animal Health Belgium S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Bioveta a.s.
Responsible authority:
  • Federal Agency For Medicines And Health Products
Authorisation number:
This information is not available for this product.
Date of authorisation status change:
Reference member state:
  • Czechia
Procedure number:
  • CZ/V/0128/001
Concerned member states:
  • Austria
  • Belgium
  • Denmark
  • France
  • Germany
  • Greece
  • Ireland
  • Italy
  • Luxembourg
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 23/01/2024
Download
French (PDF)
Published on: 14/02/2024
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 23/01/2024
Download
French (PDF)
Published on: 14/02/2024
Download
German (PDF)
Published on: 23/01/2024
Download

Labelling

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 23/01/2024
Download
French (PDF)
Published on: 23/01/2024
Download
German (PDF)
Published on: 23/01/2024
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."